Company intelligence / Profile preview

NeoManna

Rehovot / Ness Tziona, Israelagchimedes.com ↗

Ownership: Private
Development stage: Preclinical

Overview

NeoManna develops next-generation natural antimicrobial and anti-inflammatory products for the global animal health industry. Their lead product family, based on BSF oil, has achieved regulatory registration in the EU and Israel with initial commercial sales underway. Additional pipeline products target inflammation using BSF protein or address unmet needs in animal health through novel insect-derived solutions.

Therapeutic areas: Infectious Diseases
Modalities: Natural antimicrobials derived from Black Soldier Fly (BSF) oil and proteinInsect-derived bioactives for feed additives
Industry: Veterinary

Drug pipeline

2 assets

NeoMAG

Pre-clinical

Indications: Animal infections

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on NeoManna.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeoManna.

Explore the full profile